Luminex Corporation Awarded Frost & Sullivan 2005 Clinical Diagnostics Technology Of The Year
AUSTIN, Texas, Nov. 14 /PRNewswire-FirstCall/ -- Luminex Corporation has announced that the Company received the 2005 Clinical Diagnostics Technology of the Year Award from Frost & Sullivan. The Frost & Sullivan annual Best Practices Awards, held November 9th, honors world-class companies for quality performance and meritorious achievements. Every year, Frost & Sullivan honors the company that has introduced a clinical diagnostics technology that shows the potential to become an industry standard, achieve a high degree of market acceptance and maintain a competitive posture in several market segments.
(Logo: http://www.newscom.com/cgi-bin/prnh/20051114/DAM039LOGO )
Luminex Chief Executive Officer, Patrick J. Balthrop, noted, "Receiving this award is a confirmation of our innovative technology and our great people. Every member of the Luminex team, our employees and our partners, had a role in Luminex receiving this significant recognition from Frost & Sullivan. The Frost & Sullivan Clinical Diagnostics Technology of the Year Award represents another validation of the leadership of our xMAP(R) technology in the clinical diagnostics marketplace. Diagnostic immunoassay and molecular testing are two of six key market segments on which Luminex is focused. The ability to multiplex, or test for multiple markers in a single sample, is becoming increasingly important in diagnostics. Through licensing agreements with market leaders, we are establishing xMAP as the technology of choice in multiplexing."
"Luminex's groundbreaking xMAP technology, with its unique versatility to perform both DNA and protein-based assays, has made its technology highly sought after in the clinical diagnostics and life sciences industries," stated Martin Nejat, Industry Analyst with Frost & Sullivan. "Featuring a flexible, open-architecture design, the xMAP technology provides a wide range of applications throughout the diagnostics and drug discovery fields, as well as in basic research, that allows the company to respond to the changing needs of the marketplace."
Luminex Corporation develops, manufactures and markets proprietary biological testing technologies with applications throughout the life sciences industry. The Company's xMAP system is an open-architecture, multi-analyte technology platform that delivers fast, accurate and cost-effective bioassay results to markets as diverse as pharmaceutical drug discovery, clinical diagnostics and biomedical research, including the genomics and proteomics research markets. The Company's xMAP technology is sold worldwide and is already in use in leading research laboratories as well as major pharmaceutical, diagnostic and biotechnology companies. Further information on Luminex Corporation or xMAP can be obtained on the Internet at http://www.luminexcorp.com .
Statements made in this release that express Luminex's or management's intentions, plans, beliefs, expectations or predictions of future events are forward-looking statements. The words "believe," "expect," "intend," "estimate," "anticipate," "will," "could," "should" and similar expressions are intended to further identify such forward-looking statements for purposes of the Private Securities Litigation Reform Act of 1995. It is important to note that the Company's actual results or performance could differ materially from those anticipated or projected in such forward-looking statements. Factors that could cause Luminex's actual results or performance to differ materially include risks and uncertainties relating to, among others, market demand and acceptance of Luminex's products, the Company's dependence on strategic partners for development, commercialization and distribution of products, fluctuations in quarterly results due to a lengthy and unpredictable sales cycle, Luminex's ability to scale manufacturing operations, potential shortages of components, competition, the timing of regulatory approvals and any modification of the Company's operating plan in response to its ongoing evaluation of its business, as well as the risks discussed under the heading "Risk Factors" in Luminex's Annual Report on Form 10-K for the year ended December 31, 2004, as filed with the Securities and Exchange Commission. The forward-looking statements contained herein represent the judgment of Luminex as of the date of this press release, and Luminex expressly disclaims any intent, obligation or undertaking to release publicly any updates or revisions to any forward-looking statements to reflect any change in Luminex's expectations with regard thereto or any change in events, conditions or circumstances on which any such statements are based.
Corporate Contact: Harriss T. Currie Vice President, Finance Chief Financial Officer Luminex Corporation 512.219.8020 hcurrie@luminexcorp.com Media Contact: Sandra G. Oak Nsight Public Relations 321.591.1508 soakpr@bellsouth.net
Photo: NewsCom: http://www.newscom.com/cgi-bin/prnh/20051114/DAM039LOGOAP Archive: http://photoarchive.ap.orgPRN Photo Desk, photodesk@prnewswire.comLuminex CorporationCONTACT: Harriss T. Currie, Vice President, Finance, Chief FinancialOfficer of Luminex Corporation, +1-512-219-8020, or hcurrie@luminexcorp.com; or media, Sandra G. Oak of Nsight Public Relations, +1-321-591-1508, orsoakpr@bellsouth.net , for Luminex Corporation
Web site: http://www.luminexcorp.com/